Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Novartis

Status and phase: Completed; Phase 3

Conditions: Atopic Dermatitis

Treatments: Drug: Pimecrolimus Cream 1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00232011

CASM981C1304

Details and patient eligibility

About

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic dermatitis. This study is a 6-month extension study following core study.

THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Sex: All

Ages: 16 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who had completed the core study and whose participation in this study was considered appropriate as judged by the investigator
• Patients who had given written informed consent to participation in this study

Exclusion criteria

• Patients who failed in treatment compliance in the core study
• Patients who had a major violation of the protocol in the core study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

160 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Pimecrolimus Cream 1%